The Global Fund to Fight HIV, TB and Malaria says it will fund the roll-out of the twice-yearly anti-HIV jab, lenacapavir, for poorer countries, including South Africa, with or without the help of the US government’s AIDS fund, PEPFAR.
Studies have shown lenacapavir is 100% effective for young women and 96% for gay and bisexual men.
In December, PEPFAR and the Global Fund announced a commitment to fund the roll-out of lenacapavir in countries they support, once the medicine is registered with regulators.
But some fear that the Trump administration’s recent termination of USAID-funded PEPFAR projects is a sign that PEPFAR will likely pull out of the deal.
That would be unwise, some experts say, especially if the Global Fund’s “investment case” is anything to go by.
Read the full story at Bhekisisa.
Source : Bhekisisa
Related HIV and Co-Infections News
-
[Press release] US and Global Fund expand commitment to long-acting HIV prevention as country rollout of lenacapavir accelerates
-
University of Manchester: Scientists develop a cheaper and more sustainable way to manufacture breakthrough HIV drug lenacapavir
-
AVAC: Abrupt shutdown of US global health supply chain raises risks for HIV, TB and malaria programs
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.